STOCK TITAN
  1. Home
  2. Sec-filings
  3. TRDA
  4. [Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Entrada holder MPM funds sell 259,837 shares

Entrada Therapeutics, Inc. (TRDA) reported that investment funds affiliated with MPM BioVentures, which are ten percent owners, made indirect open-market sales of an aggregate 259,837 shares of Common Stock over three days in September 2026.

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) reported that investment funds affiliated with MPM BioVentures, which are ten percent owners, made indirect open-market sales of an aggregate 259,837 shares of Common Stock over three days in September 2026. The sales were executed at weighted average prices between roughly $7.01 and $7.70 per share, with the shares held across multiple MPM partnerships and LLCs. Each reporting person disclaims beneficial ownership beyond its pecuniary interest, and no Rule 10b5-1 trading plan is reported.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold 259,837 shs ($1.91M)
Type Security Shares Price Value
Sale Common Stock F8, F9, F4, F10 28,837 $7.13 $206K
Sale Common Stock F5, F6, F4, F7 192,500 $7.41 $1.43M
Sale Common Stock F1, F2, F3, F4 38,500 $7.11 $274K
Holdings After Transaction: Common Stock — 3,885,115 shares (Indirect, See Footnote)
Footnotes (10)
  1. F1. The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
  2. F2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  3. F3. The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.
  4. F4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  5. F5. The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.
  6. F6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  7. F7. The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
  8. F8. The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.
  9. F9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  10. F10. The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.
Total shares sold 259,837 shares Aggregate indirect sales by MPM-affiliated entities reported for September 4, 8, and 9, 2026
Shares sold on September 4, 2026 38,500 shares Indirect sale of Common Stock with weighted average price disclosure
Weighted average price September 4, 2026 $7.11 per share Sale price range from $7.01 to $7.16 per share
Shares sold on September 8, 2026 192,500 shares Indirect sale of Common Stock
Weighted average price September 8, 2026 $7.41 per share Sale price range from $6.97 to $7.70 per share
Shares sold on September 9, 2026 28,837 shares Indirect sale of Common Stock
Weighted average price September 9, 2026 $7.13 per share Sale price range from $7.02 to $7.54 per share
Post-transaction holdings, MPM BioVentures 2014, L.P. 1,764,167 shares Reported held after the September 9, 2026 transactions
weighted average sale price financial
"Price represents the weighted average sale price of the shares sold."
pecuniary interest financial
"disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest"
indirect financial
"The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B)..."
ten percent owner regulatory
"Reporting persons are indicated as ten percent owners of Entrada Therapeutics, Inc."

FAQ

What insider activity did TRDA disclose in this Form 4?
The filing reports that funds affiliated with MPM BioVentures, as ten percent owners, indirectly sold a total of 259,837 shares of Entrada Therapeutics Common Stock in open-market transactions over September 4, 8, and 9, 2026.

How many TRDA shares were sold on each reported date?
On September 4, 2026, 38,500 shares were sold; on September 8, 2026, 192,500 shares were sold; and on September 9, 2026, 28,837 shares were sold, all indirectly by MPM BioVentures–affiliated entities.

What prices did the MPM entities receive for the TRDA share sales?
Reported per-share figures are weighted averages. For September 4, the weighted average was $7.11 with a range of $7.01–$7.16. For September 8, the weighted average was $7.41 with a range of $6.97–$7.70. For September 9, the weighted average was $7.13 with a range of $7.02–$7.54.

Were the TRDA insider sales made under a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox is not checked, and the footnotes describe the transactions and ownership structure but do not state that the sales were made pursuant to a Rule 10b5-1 trading plan.

Who actually holds the TRDA shares for the reporting persons?
The shares are held by several entities: MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2018, L.P., MPM BioVentures 2018(B), L.P., and MPM Asset Management Investors BV2018 LLC, with each reporting person disclaiming beneficial ownership beyond its pecuniary interest.

How many TRDA shares do the MPM entities report holding after the latest transaction?
After the September 9, 2026 transactions, the entities report holdings including 1,764,167 shares by MPM BioVentures 2014, L.P., 117,667 by MPM BioVentures 2014(B), L.P., 60,722 by MPM Asset Management Investors BV2014 LLC, 1,810,592 by MPM BioVentures 2018, L.P., 96,232 by MPM BioVentures 2018(B), L.P., and 35,735 by MPM Asset Management Investors BV2018 LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MPM BioVentures 2014, L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/04/2026S38,500(1)D$7.11(2)4,106,452ISee Footnote(3)(4)
Common Stock09/08/2026S192,500(5)D$7.41(6)3,913,952ISee Footnote(4)(7)
Common Stock09/09/2026S28,837(8)D$7.13(9)3,885,115ISee Footnote(4)(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
MPM BioVentures 2014, L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
EVNIN LUKE
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
GADICKE ANSBERT
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Foley Todd
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 (B), L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM Asset Management Investors BV2014 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BioVentures 2014 GP LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM BIOVENTURES 2018 (B), L.P.
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
(Last)(First)(Middle)
C/O MPM BIOIMPACT
399 BOYLSTON STREET, SUITE 1100
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.
4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
5. The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.
6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
7. The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
8. The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.
9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
10. The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.
Remarks:
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.
/s/ Ansbert Gadicke09/09/2026
/s/ Luke Evnin09/09/2026
/s/ Todd Foley09/09/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P.09/09/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC09/09/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC09/09/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P.09/09/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC09/09/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.09/09/2026
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC09/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on TRDA

Trending in the feed

Open the live feed